Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | PGR | P06401 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115188 | 0.85 | PGR (0.47) | ALDH1A1KDM4EGRIA2GRIA4SMN1; SMN2 | |
| SCHEMBL509687 | 0.82 | MGLL (0.38) | GRIA2GRIA4PGRKCNH2 | |
| SCHEMBL4099456 | 0.81 | ALDH1A1 (0.37) | ALDH1A1KDM4ESMN1; SMN2HPGDMAPK1 | |
| SCHEMBL4959656 | 0.81 | PTGDR2 (0.42) | ALDH1A1KDM4EGRIA2GRIA4PGR | |
| SCHEMBL4099713 | 0.77 | PGR (0.42) | ALDH1A1KDM4EPGRHPGDUSP2 | |
| SCHEMBL4098727 | 0.76 | ALDH1A1 (0.34) | ALDH1A1KDM4ESMN1; SMN2PGRHPGD | |
| SCHEMBL4110055 | 0.76 | ALDH1A1 (0.34) | ALDH1A1KDM4ESMN1; SMN2PGRHPGD | |
| SCHEMBL4104516 | 0.76 | KCNH2 (0.36) | ALDH1A1KDM4ESMN1; SMN2USP2KCNH2 | |
| SCHEMBL4102883 | 0.76 | PGR (0.44) | ALDH1A1KDM4ESMN1; SMN2PGRKCNH2 | |
| SCHEMBL4112540 | 0.76 | PGR (0.38) | ALDH1A1KDM4ESMN1; SMN2PGRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060241125-A1 | Compounds useful in therapy | BRADLEY PAUL A | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241125-A1 | Compounds useful in therapy | CBR3, GPER1, CBR1 | ALDH1A1 881/4885KDM4E 3328/4885GRIA2 3937/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | ALDH1A1 974/4885KDM4E 3493/4885GRIA2 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.